In our study, we found that plasma exosome proteins RPL13 and RPL14 were highly expressed in IM-R CML patients, and could be used as potential markers for predicting and monitoring IM response in CML patients. This evidence concerns the gene RPL14 and chronic myelogenous leukemia, BCR-ABL1 positive.